Breast CancerNCT01152606
A Study of Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin
An observational study of Breast Cancer, run by Hoffmann-La Roche at 205 sites in 9 countries.
Trial summary
This is a single cohort observational safety study. All patients will be treated and monitored according to the local clinical practice. No additional procedures/patient visits in comparison with the usual clinical practice are planned for the study. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Breast Cancer
- What is being tested?
- trastuzumab [Herceptin]
- How many people
- 3,942 participants
- Where
- 205 sitesin 9 countries
- Study dates
- 30 Aug 2007to 31 May 2016
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: HER2-positive Breast Cancer
Who may be able to join
- All patients who are considered candidates to receive Herceptin for this indication
Who cannot join
- Patients for whom Herceptin is contraindicated
Trial locations and contacts
205 sites in 9 countries.
205 sites in 9 countries
Germany69 sites
Studienzentrum Aschaffenburg
Aschaffenburg, 63739
Internist; Praxis Für Haemotologie & Onkologie
Bad Soden, 65812
Brustzentrum Bassum
Bassum, 27211
Onkologische Schwerpunktpraxis Kurfürstendamm
Berlin, 10707
Praxis Dr. Schoenegg
Berlin, 10719
DRK Kliniken Berlin Köpenick, Frauenklinik
Berlin, 12559
Praxis Dr Geuther
Berlin, 14195
Onkologische Schwerpunktpraxis Bielefeld; Haemotologie & Internistische onkologie
Bielefeld, 33604
Medizinisches Versorgungszentrum Bonn
Bonn, 53111
Universitätsklinikum Bonn; Zentrum für Geburtshilfe und Frauenheilkunde
Bonn, 53127
Gemeinschaftspraxis Für Haematologie/Onkologie
Cologne, 50677
Uniklinik Köln; Klinik Für Frauenheilkunde
Cologne, 50931
Med. Versorgungszentrum Filiale Donauwörth Onkologisches Zentrum
Donauwörth, 86609
Onkologisches Zentrum; Oncology
Donauwörth, 86609
St. Johannes Hospital
Dortmund, 44137
Praxis im Elbcenter 1 in Dresden-Pieschen; Dr. med. Thomas Goehler & Dipl.-Med. Steffen Doerfel
Dresden, 01127
BAG Freiberg-Richter, Jacobasch, Illmer, Wolf
Dresden, 01307
Universitätsklinikum "Carl Gustav Carus"; Frauenheilkunde und Geburtshilfe
Dresden, 01307
Universitätsklinikum Düsseldorf; Frauenklinik
Düsseldorf, 40225
Kreisklinik Ebersberg; Abteilung für Gynäkologie & Geburtshilfe
Ebersberg, 85560
Universitätsklinikum Erlangen; Frauenklinik
Erlangen, 91054
St Antonius Hospital; Frauenklinik
Eschweiler, 52249
Uniklinik Essen; Gynäkologie
Essen, 45122
Hämatologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus
Frankfurt am Main, 60389
Praxis für Interdisziplinäre Onkologie und Hämatologie GbR
Freiburg im Breisgau, 79110
Klinikum Fulda gAG; Frauenklinik
Fulda, 36043
Klinikum St. Georg GmbH; Franziskus-Hospital Harderberg; Klinik für Gynaekologie und Geburtshilfe
Georgsmarienhütte, 49124
Wilhelm-Anton-Hospital Klinik f.Hämatologie und internistische Onkologie
Goch, 47574
Martin-Luther-Universität Halle-Wittenberg
Halle, 06097
Universitätsklinikum Hamburg-Eppendorf; Frauenklinik
Hamburg, 20246
Kooperatives Mammazentrum Hamburg Krankenhaus Jerusalem
Hamburg, 20357
Praxis Harburger Ring
Hamburg, 21073
Iorc-Innovation Onkologie& Research& Consulting Gmbh; Praxis Lerchenfeld Hamburg
Hamburg, 22081
Dres. Sigrun Müller-Hagen Mathias Bertram und Ulrich Stein
Hamburg, 22457
SANA Klinikum Hameln-Pyrmont; Frauenklinik / Brustzentrum
Hamelin, 31785
Diakovere Henriettenstift, Frauenklinik
Hanover, 30559
Medizinische Hochschule Zentrum Frauenheilkunde Abt.Gynäkologische Onkologie
Hanover, 30625
Stiftung Kathol. Krankenhaus Marienhospital Herne Klinik Mitte Frauenklinik
Herne, 44625
Universitaetsklinikum des Saarlandes; Klinik f. Frauenheilkunden und Geburtshilfe
Homburg/Saar, 66424
Universitätsklinikum Jena; Klinik und Poliklinik für Frauenheilkunde und Fortpflanzungsmedizin
Jena, 07747
Westpfalz-Klinikum GmbH; Klinik für Frauenheilkunde und Geburtshilfe
Kaiserslautern, 67655
Gemeinschaftspraxis Dr. Siehl & Dr. Soeling
Kassel, 34119
Systemedic Frauenarzte Pruener Gang
Kiel, 24103
Asklepios Klinik; Abt. Gynäkologie
Langen, 63225
Klinik Lippe Lemgo; Medizinische Klinik II/Haematoonkologie
Lemgo, 32657
Universitätsklinikum Schleswig-Holstein / Campus Lübeck; Klinik für Frauenheilkunde und Geburtshilfe
Lübeck, 23538
Onkologische Gemeinschaftspraxis
Magdeburg, 39104
Universitätsmedizin Mainz; Klinik u. Poliklinik f. Geburtshilfe u. Frauenheilkunde
Mainz, 55131
Universitätsklinikum Marburg; Gynäkologie
Marburg, 35043
Ev. Krankenhaus
Mülheim, 45468
Gemeinschaftspraxis für Hämatologie und Onkologie
Münster, 48149
Praxis Für Haematologie & Onkologie Dr. B. Otremba
Oldenburg, 26121
Praxis Frau Dr. Schwarz
Oranienburg, 16515
Klinikum Passau; 2. Medizinische Klinik; Onkologie und Hämatologie
Passau, 94032
Krankenhaus Rheinfelden; Frauenklinik
Rheinfelden, 79618
Agaplesion Diakonieklinikum Rotenburg
Rotenburg (Wümme), 27356
Caritas Klinik St. Theresia -Frauenklinik Brustzentrum
Saarbrücken, 66113
Praxis Dr. Wagner
Saarbrücken, 66113
Klinik Saarbrücken Ggmbh; Brustzentrum
Saarbrücken, 66119
DRK Krankenhaus Saarlouis; Kooperatives Brustzentrum
Saarlouis, 66740
Marienkrankenhaus Abt. Gynäkologie und Geburtshilfe
Saint Wendel, 66606
MVZ für Hämatologie, Onkologie, Strahlentherapie und Palliativmedizin -; Klinik Dr. Hancken
Stade, 21680
Johanniter-Krankenhaus
Stendal, 39576
Klinik Der Hansestadt Stralsund Gmbh; Frauenklinik
Stralsund, 18435
Klinikum Traunstein
Traunstein, 83278
Klinikum Mutterhaus der Borromaeerinnen gGmbH; Haematologie/Onkologie
Trier, 54290
Katharinen-Hospital gGmbH
Unna, 59423
Kliniken Nordoberpfalz; Klinikum Weiden; Brustzentrum
Weiden, 92637
Gemeinschaftspraxis Hämatologie / Onkologie
Wiesbaden, 65191
Italy58 sites
USL 8 Ospedale San Donato; Oncology Endocrinology
Arezzo, Tuscany, 52100
Azienda Ospedaliera S.G. Moscati; Division of Medical Oncology
Avellino, Campania, 83100
Irccs Centro Di Riferimento Oncologico (CRO); Dipartimento Di Oncologia Medica
Aviano, Friuli Venezia Giulia, 33081
Ospedale Santa Maria Annunziata; Oncologia
Bagno a Ripoli, Tuscany, 50012
Asst Papa Giovanni XXIII; Oncologia Medica
Bergamo, Lombardy, 24128
Az. Osp. S. Orsola Malpighi; Istituto Di Oncologia Seragnoli
Bologna, Emilia-Romagna, 40138
Az. Osp. Spedali Civili; Divisione Di Oncologia - Iii Medicina
Brescia, Lombardy, 25123
A.O.U. Cagliari-P.O. Monserrato;U.O. Oncologia
Cagliari, Sardinia, 09100
Fondazione Del Piemonte Per L'oncologia Ircc Di Candiolo; Dipartimento Oncologico
Candiolo, Piedmont, 10060
Ospedale Di Casalpusterlengo; Day Hospital Oncologico
Casalpusterlengo, Lombardy, 20071
Centro Catanese Di Oncologia; Oncologia Medica
Catania, Sicily, 95126
Az. Osp. Pugliese; Dh Oncologico
Catanzaro, Calabria, 88100
Policlinico Ospedaliero Ss Annunziata; U.O. Di Clinica Oncologica
Chieti, Abruzzo, 66100
Ospedale Valduce; Dept. Di Oncologia Medica
Como, Lombardy, 22100
Arcispedale S.Anna; Oncologia Medica
Cona (Ferrara), Veneto, 44124
Az. Osp. Mariano Santo; Centro Oncologico
Cosenza, Calabria, 87100
Ospedale S. Croce Di Fano; Servizio Oncologia
Fano, The Marches, 61032
Azienda Ospedaliero-Universitaria Careggi;S.C. Oncologia Medica 1
Florence, Tuscany, 50139
IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A
Genoa, Liguria, 16132
Ospedale S. Andrea Est Felettino; Oncologia Medica
La Spezia, Liguria, 19100
Ospedale S. Maria Goretti; Divisione Di Oncologia Medica
Latina, Lazio, 04100
Ospedale Vito Fazzi; Div. Oncoematologia
Lecce, Apulia, 73100
ASST DI LECCO; Oncologia Medica
Lecco, Lombardy, 23900
ASST OVEST MILANESE; Oncologia Medica
Legnano, Lombardy, 20025
Ospedale Campo Di Marte; Dipartimento Oncologico
Lucca, Tuscany, 55100
Az. Osp. Carlo Poma; Divisione Di Oncologia Medica
Mantua, Lombardy, 46100
Opspedale Morgagni - Pierantoni; Dept. Di Oncologia Medica
Meldola, Emilia-Romagna, 47014
Istituto Europeo Di Oncologia
Milan, Lombardy, 20141
Asst Santi Paolo E Carlo; Unita Operativa Di Oncologia Medica
Milan, Lombardy, 20142
Az. Osp. Cardarelli; Divisione Di Oncologia
Naples, Campania, 80131
Ist. Uni Federico Ii; Divisione Di Oncologia Medica - Dpt. Di Medicina Interna
Naples, Campania, 80131
Istituto Tumori Fondazione Pascale; Endocrinologia Oncologica
Naples, Campania, 80131
Ospedale S. Gennaro; Oncologia Medica
Naples, Campania, 80136
Az. Osp. M. Ascoli G. Di Cristina; Oncologia Medica
Palermo, Sicily, 90127
La Maddalena Casa Di Cura Di Alta Specialita; Oncologia Chirurgica
Palermo, Sicily, 90146
Fondazione Salvatore Maugeri; Divisione Di Oncologia Medica
Pavia, Lombardy, 27100
Fondazione Salvatore Maugeri; Servizio Di Prevenzione Oncologica
Pavia, Lombardy, 27100
Irccs Policlinico S. Matteo - Uni Pavia; Clinica Medica I Div. Med. Int. Onc. Medica E Gastroent.
Pavia, Lombardy, 27100
Azienda Usl 7; Dept. Oncologico
Poggibonsi, Tuscany, 53036
Ospedale Degli Infermi Di Biella; Reparto Oncologia Medica
Ponderano (BI), Piedmont, 13875
Ospedale San Carlo; Day Hospital Oncologia Medica
Potenza, Basilicate, 85100
Az. Osp. ; Divisione Di Oncologia
Ragusa, Sicily, 97100
Ospedale Provinciale Santa Maria delle Croci
Ravenna, Emilia-Romagna, 48100
Ospedale Oncologico Regionale; U.O. Oncologia Medica Ed Ematologia
Rionero in Vulture, Basilicate, 85028
Ospedale San Giacomo in Augusta; Reparto Oncologia
Rome, Lazio, 00100
Policlinico Universitario Campus Biomedico; Uoc Oncologia Medica
Rome, Lazio, 00128
Azienda Complesso Ospedaliero S. Filippo Neri; Divisione Di Oncologia Medica
Rome, Lazio, 00135
Istituto Regina Elena; Oncologia Medica A
Rome, Lazio, 00168
Policlinico Militare Di Roma; Reparto Di Oncologia
Rome, Lazio, 00184
IRCCS Ospedale Casa Sollievo Della Sofferenza; Oncologia
San Giovanni Rotondo, Apulia, 71013
Polo Ospedaliero Santorso
Santorso, Veneto, 36014
Azienda Ospedaliero Universitaria Di Sassari;Oncologia
Sassari, Sardinia, 07100
Ospedale Santa Chiara; Oncologia Medica
Trento, Trentino-Alto Adige, 38100
Centro Soc. Oncologico, Azienda Sanitaria Universitaria Integrata Trieste; CENTRO ONCOLOGICO
Trieste, Friuli Venezia Giulia, 34100
A.O. Città della Salute e della Scienza - Presidio Molinette; divisione oncologia medica
Turin, Piedmont, 10126
Ospedale Sant'Anna - Uni Di Torino; Unita Di Oncologia Ginecologica
Turin, Piedmont, 10126
Ospedale Di Circolo; Centro Di Senologia
Varese, Lombardy, 21100
Ospedale Civile S. Bortolo; Divisione Di Oncologia
Vicenza, Veneto, 36100
United Kingdom23 sites
Aberdeen Royal Infirmary; Medical Oncology Dept
Aberdeen, AB25 2ZN
Belfast City Hospital; Dept of Oncology
Belfast, BT9 7AB
Velindre Cancer Centre; Oncology Dept
Cardiff, CF14 2TL
Broomfield Hospital; Oncology
Chelmsford, CM1 7ET
Ninewells Hospital; Dept of Radiotherapy & Oncology
Dundee, DD1 9SY
Royal Devon & Exeter Hospital; Oncology Centre
Exeter, EX2 5DW
Glasgow Western Infirmary; Dept of Radiotherapy
Glasgow, G11 6NT
Huddersfield Royal Infirmary
Huddersfield, HD3 3EA
Queen Elizabeth Hospital
Kings Lynn, PE30 4ET
St Thomas Hospital; Medicine Div.
London, SE1 7EH
St George'S Hospital; Oncology Research Office /Oncology Opd
London, SW17 ORE
Charing Cross Hospital; Medical Oncology.
London, W6 8RF
Christie Hospital; Breast Cancer Research Office
Manchester, M20 4QL
James Cook Uni Hospital
Middlesbrough, TS4 3BW
Newcastle General Hospital
Newcastle upon Tyne, NE4 6BE
Royal Preston Hosptial
Preston, PR2 9HT
Oldchurch Hospital
Romford, RM7 0BE
Salisbury District General Hospital; Medical Oncology Dept
Salisbury, SP2 8BJ
Royal Shrewsbury Hospitals Nhs Trust; Oncology
Shrewsbury, SY3 8XQ
Southampton General Hospital; Medical Oncology
Southampton, SO16 6YD
Worthing Hospital; Sussex Oncology Centre, Worthing Breast Unit
Worthing, B11 2DH
Yeovil District Hospital; Macmillan Cancer Unit
Yeovil, BA21 4AT
Airedale General Hospital; Oncology
York, BD20 6TD
Belgium16 sites
ZNA Middelheim
Antwerp, 2020
CH EpiCURA Site Louis Caty
Baudour, 7331
AZ KLINA
Brasschaat, 2930
AZ Sint Jan
Bruges, 8000
HIS (Etterbeek Ixelles)
Brussels, 1050
Hospital Erasme; Neurologie
Brussels, 1070
Cliniques Universitaires St-Luc
Brussels, 1200
UZ Antwerpen
Edegem, 2650
AZ Groeninge (Kennedylaan)
Kortrijk, 8500
CHU Sart-Tilman
Liège, 4000
Clinique Ste-Elisabeth
Namur, 5000
Clinique St Pierre asbl
Ottignies, 1340
AZ Delta (Campus Wilgenstraat)
Roeselare, 8800
AZ Nikolaas (Sint Niklaas)
Sint-Niklaas, 9100
AZ Turnhout Sint Elisabeth
Turnhout, 2300
Sint Augustinus Wilrijk
Wilrijk, 2610
Austria15 sites
Lkh-Univ. Klinikum Graz; Klinik Für Gynäkologie
Graz, 8036
LKH-UNIV. KLINIKUM GRAZ; Klinische Abteilung für Onkologie
Graz, 8036
Lhk Klagenfurt; Abt. Für Gynäkologie
Klagenfurt, 9026
LKH Hochsteiermark; Abt. für Innere Medizin
Leoben, 8700
Ordensklinikum Linz Barmherzige Schwestern; Abt. fur Innere Medizin 1
Linz, 4010
Lhk Feldkirch; Interne Medizin Abt.
Rankweil, 6830
Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt.
Salzburg, 5020
A. Ö. Krankenhaus Der Barmherzigen Brüder; Abt. Für Chirurgie
Sankt Veit an der Glan, 9300
A.Ö. Lhk; Ii. Medizinische Abt. Mit Schwerpunkt Gaströnter. & Onkologie
Steyr, 4400
Krankenanstalt Rudolfstiftung; I. Med. Abt.
Vienna, 1030
Medizinische Universität Wien; Univ.Klinik für Frauenheilkunde - Klinik für Gynäkologie
Vienna, 1090
Medizinische Universität Wien; Univ.Klinik für Innere Medizin I
Vienna, 1090
Wilhelminenspital; I. Medizinische Abt.
Vienna, 1160
Lhk Vöcklabruck; Ii. Interne Abt.
Vöcklabruck, 4840
Klinikum Kreuzschwestern Wels; Iv. Interne Abt.
Wels, 4600
Spain9 sites
Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico; Servicio de Oncologia
Jaén, 23007
Hospital Regional Universitario Carlos Haya
Málaga, 29010
Hospital General de Mataro; Servicio de Oncologia
Mataró, Barcelona, 08304
Hospital de Navarra; Servicio de Oncologia
Navarra, Navarre, 31008
Corporacio Sanitaria Parc Tauli; Servicio de Oncologia
Sabadell, Barcelona, 08208
Hospital Universitario de Canarias;servicio de Oncologia
San Cristóbal de La Laguna, Tenerife, 38320
Hospital Universitario Virgen del Rocio; Servicio de Oncologia
Seville, 41013
Complejo Hospitalario de Toledo- H. Virgen de la Salud; Servicio de Oncologia
Toledo, 45004
Hospital Universitario Miguel Servet; Servicio Oncologia
Zaragoza, 50009
Sweden9 sites
Gävle sjukhus onkologkliniken
Gävle, 80187
Lanssjukhuset Ryhov; Onkologkliniken
Jönköping, 55185
Länssjukhuset Kalmar; Oncology
Kalmar, 39185
Centralsjukhuset Karlstad, Onkologkliniken
Karlstad, 65185
Uni Hospital Linkoeping; Dept. of Oncology
Linköping, 58185
Skånes University Hospital, Skånes Department of Onclology
Lund, 22185
Karolinska Hospital; Oncology - Radiumhemmet
Stockholm, 17176
Länssjukhuset Sundsvall, Onkologkliniken
Sundsvall, 85186
Norrlands Universitetssjukhus, Umeå, Cancercentrum; Dept of Oncology
Umeå, 90185
Hungary4 sites
Semmelweis Egyetem Onkologiai Központ
Budapest, 1083
Municipal Hospital of Uzsoki Utca; Centre of Oncoradiology
Budapest, 1145
Josa Andras Korhaz; Dept of Oncoradiology
Nyíregyháza, 4400
Vas Megyei Markusovszky Korhaz ; Pulmonology
Szombathely, 9700
Poland2 sites
Regionalne Centrum Onkologi; Oddzial Chorob Wewnetrznych I Onkologii
Bydgoszcz, 85-796
Oddzial Chemioterapii Szpitala Klinicznego Nr 1 w Poznaniu
Poznan, 60-569
About this study
Official title: An Observational Study of Cardiac Events in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin
This is a single cohort observational safety study. All patients will be treated and monitored according to the local clinical practice. No additional procedures/patient visits in comparison with the usual clinical practice are planned for the study. Data will be collected from centre's medical records for up to 5 years or death.
- Conditions
- Breast Cancer
- Being tested
- trastuzumab [Herceptin]
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
trastuzumab [Herceptin]Drug
There is no planned investigational product or a treatment regimen prescribed by this protocol. Decision about a treatment regimen will be made according to the local practice and in the best interest of individual patients.
| Study group | Role | What they receive |
|---|---|---|
| Cohort | Not described Receives: Drug: trastuzumab [Herceptin] |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of symptomatic congestive heart failure\n(CHF) using New York Heart Association class II, III and IV, and cardiac death
Measured: On treatment and up to 5 years follow-up
Secondary outcomes (2)
Time to onset and the time to recovery of symptomatic congestive heart failure
Measured: On treatment and up to 5 years follow-up
Incidence of asymptomatic cardiac failure and other significant cardiac conditions
Measured: On treatment and up to 5 years follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jun 2010 (estimated)
- Study start30 Aug 2007
- Primary completion31 May 2016
- Study completion31 May 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- More trials run by Hoffmann-La RocheThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 3,942 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hoffmann-La Roche
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Trials, Study director, Hoffmann-La Roche
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01152606
- Sponsor's protocol ID
- BO20652
- Status last verified
- Jan 2018
- First submitted
- 28 Jun 2010
- Last updated
- 25 Jan 2018
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Jan 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Observational Study of Cardiac Events in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin
- ClinicalTrials.gov ID
- NCT01152606
- Acronym / sponsor ID
- BO20652
- Conditions
- Breast Cancer
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 3,942 participants (actual)
- Lead sponsor
- Hoffmann-La RocheIndustry (pharma, biotech, devices)
- Study start
- 30 Aug 2007 (actual)
- Primary completion
- 31 May 2016 (actual)
- Study completion
- 31 May 2016 (actual)
- First posted
- 29 Jun 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a single cohort observational safety study. All patients will be treated and monitored according to the local clinical practice. No additional procedures/patient visits in comparison with the usual clinical practice are planned for the study. Data will be collected from centre's medical records for up to 5 years or death.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Cohort | – | Drug: trastuzumab [Herceptin] |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- HER2-positive Breast Cancer
Key inclusion criteria (1 listed)
- All patients who are considered candidates to receive Herceptin for this indication
Key exclusion criteria (1 listed)
- Patients for whom Herceptin is contraindicated
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| trastuzumab [Herceptin]There is no planned investigational product or a treatment regimen prescribed by this protocol. Decision about a treatment regimen will be made according to the local practice and in the best interest of individual patients. | Drug | Cohort |
Primary outcome
Incidence of symptomatic congestive heart failure\n(CHF) using New York Heart Association class II, III and IV, and cardiac death
Time frame: On treatment and up to 5 years follow-up
2 secondary outcomes
Time to onset and the time to recovery of symptomatic congestive heart failure
Time frame: On treatment and up to 5 years follow-up
Incidence of asymptomatic cardiac failure and other significant cardiac conditions
Time frame: On treatment and up to 5 years follow-up
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Jan 2018.
Related trials for Breast Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clinical Trials study director
Hoffmann-La Roche
205 sites in 9 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Breast Cancer, run by Hoffmann-La Roche at 205 sites in 9 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Jan 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 205 sites in Germany, Italy, United Kingdom, Belgium, Austria and 4 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of symptomatic congestive heart failure\n(CHF) using New York Heart Association class II, III and IV, and cardiac death (time frame: On treatment and up to 5 years follow-up). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jan 2018.